Micro Labs Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Micro Labs Limited Pharmaceutical Export Portfolio Dataset — 76 Products, $463.6M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Micro Labs Limited — Pharmaceutical Exporter Profile (2026) | 76 Products, $463.6M Trade | TransData Nexus

Product Portfolio — Top 30 by Export Value

Micro Labs Limited exports 76 pharmaceutical products across 21 therapeutic categories. Market leader (#1 exporter) in 6 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Amoxicillin	Antibiotics	$63.3M	1,266	10.4%	1
2	Potassium	Nutritional Supplements	$25.1M	555	3.9%	7
3	Gabapentin	CNS & Psychiatric	$22.7M	519	2.6%	11
4	Losartan	Cardiovascular	$20.5M	676	6.8%	2
5	Esomeprazole	Gastrointestinal	$20.4M	409	4.5%	4
6	Cefixime	Advanced Antibiotics	$19.1M	697	11.0%	1
7	Omeprazole	Gastrointestinal	$17.2M	344	2.7%	4
8	Metformin	Diabetes & Endocrine	$16.2M	552	3.5%	7
9	Amlodipine	Cardiovascular	$16.0M	628	0.1%	8
10	Clarithromycin	Antibiotics	$15.4M	308	15.7%	1
11	Atorvastatin	Cardiovascular	$13.7M	413	1.3%	11
12	Telmisartan	Cardiovascular	$8.9M	659	0.1%	7
13	Diclofenac	Analgesics & Antipyretics	$8.8M	177	2.4%	8
14	Ofloxacin	Advanced Antibiotics	$8.4M	373	2.8%	5
15	Hydrochlorothiazide	Diuretics	$8.3M	326	2.0%	4
16	Cetirizine	Antihistamines & Allergy	$7.8M	213	4.4%	5
17	Fluoxetine	CNS & Psychiatric	$7.7M	154	3.3%	3
18	Dapagliflozin	Advanced Diabetes Medications	$7.7M	442	15.5%	2
19	Gliclazide	Advanced Diabetes Medications	$7.6M	205	2.5%	4
20	Celecoxib	Analgesics & Antipyretics	$6.8M	201	5.1%	5
21	Trimethoprim	Advanced Antibiotics	$6.0M	121	21.8%	1
22	Sulfamethoxazole	Advanced Antibiotics	$5.8M	117	28.1%	1
23	Isoniazid	Tuberculosis Medications	$5.6M	163	0.2%	6
24	Pantoprazole	Gastrointestinal	$5.6M	194	0.4%	12
25	Kit	Medical Devices & Diagnostics	$5.5M	193	1.3%	9
26	Azithromycin	Antibiotics	$5.5M	110	3.0%	3
27	Glimepiride	Diabetes & Endocrine	$5.3M	439	7.0%	2
28	Clopidogrel	Cardiovascular	$5.2M	217	2.1%	15
29	Levofloxacin	Antibiotics	$5.0M	365	7.0%	2
30	Ethambutol	Tuberculosis Medications	$4.8M	97	0.4%	5

Micro Labs Limited exports 76 pharmaceutical products across 21 therapeutic categories with a total export value of $463.6M. The company is the #1 Indian exporter in 6 products: Amoxicillin, Cefixime, Clarithromycin, Trimethoprim, Sulfamethoxazole. The top category is Antibiotics (21.2% of portfolio), followed by Cardiovascular (17.3%), reflecting a diversified portfolio where the top 5 products account for only 32.8% of total value.

Showing top 30 of 76 products. Contact us for complete data.

Micro Labs Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

Micro Labs Limited, established in 1973 by the visionary G.C. Surana, is a prominent Indian multinational pharmaceutical company headquartered in Bengaluru, Karnataka. The company operates as a privately held entity, with its Corporate Identification Number (CIN) U24232KA1973PLC002401. As of the fiscal year 2023, Micro Labs reported an estimated revenue of ₹5,300 crore, reflecting its significant presence in the pharmaceutical industry. The workforce comprises over 10,000 employees, underscoring its expansive operations. The official website, microlabsltd.com, provides comprehensive information about the company's products and services.

2Manufacturing Facilities

Micro Labs operates 14 state-of-the-art manufacturing plants across India, strategically located in regions such as Sikkim, Goa, Kerala, and Karnataka. These facilities are certified for Good Manufacturing Practices (GMP) and cater to both regulated and emerging markets. The company's manufacturing capabilities span diverse therapeutic areas, including Cardiology, Diabetology, Pain Management, Dermatology, Ophthalmology, and Neurology.

3Key Leadership

The leadership of Micro Labs is helmed by Chairman and Managing Director Dilip Surana, who has been instrumental in steering the company's growth and strategic direction. Anand Surana serves as the Joint Managing Director, contributing significantly to the company's operations and expansion initiatives. The leadership team is further strengthened by other key executives, including Sheetal Mudda, Ashok Jain, Ramchandra Gadegone, and Prashanth B, who play pivotal roles in various facets of the organization.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Micro Labs Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Micro Labs has established a robust presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. In the U.S., the company has a wholly owned subsidiary, Micro Labs USA, Inc., which markets high-quality, affordable generic medicines. These products are manufactured in US FDA-approved facilities in Goa and Bangalore, India, focusing on oral solid tablets and capsules, injections, ophthalmic, and oral solutions. In Europe, Micro Labs has launched its products, adhering to stringent regulatory standards. The company's commitment to quality is further demonstrated by its facilities being accredited by the US FDA and UK MHRA, ensuring compliance with international standards.

2Emerging Markets

Micro Labs has strategically expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's acquisition of Swiss Pharma Nigeria Limited (Swipha) in 2016 exemplifies its commitment to penetrating the African market. Additionally, Micro Labs has been actively involved in social responsibility programs in education, healthcare, rural development, and environmental protection, contributing to the development of local communities in these regions.

3Geographic Strategy

Micro Labs Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Micro Labs' commitment to quality is evident in its FDA facility registrations and approved Abbreviated New Drug Applications (ANDAs). The company's facilities in Goa and Bangalore, India, are US FDA-approved, ensuring compliance with stringent regulatory standards. Micro Labs USA, Inc. currently has more than 40 FDA-approved generic products and has filed over twenty-five ANDAs with the FDA at various stages of review, with plans to file ten to fifteen ANDAs annually. This proactive approach underscores the company's dedication to expanding its portfolio in the U.S. market.

2WHO & EU GMP

Micro Labs' manufacturing facilities are certified for Good Manufacturing Practices (GMP) and cater to both regulated and emerging markets. The company's commitment to quality is further demonstrated by its facilities being accredited by the US FDA and UK MHRA, ensuring compliance with international standards. These certifications reflect Micro Labs' adherence to stringent quality standards, facilitating access to global markets.

3CDSCO & Indian Regulatory

Micro Labs Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Micro Labs operates in a competitive pharmaceutical industry, with several key players in overlapping therapeutic categories. The company's market share and position vary across different segments, with a notable presence in pain management, cardiology, and anti-infectives. The competitive landscape is characterized by the presence of both domestic and international pharmaceutical companies, each vying for market share through product innovation, quality, and distribution networks. Micro Labs' strategic focus on quality, regulatory compliance, and global expansion positions it favorably in this competitive environment.

2Key Differentiators

Micro Labs' key differentiators include its commitment to quality, as evidenced by its state-of-the-art manufacturing facilities and adherence to international regulatory standards. The company's diverse therapeutic portfolio, encompassing areas such as Cardiology, Diabetology, Pain Management, Dermatology, Ophthalmology, and Neurology, allows it to cater to a wide range of medical needs. Additionally, Micro Labs' global presence and robust distribution network enable it to effectively serve both domestic and international markets. These strengths collectively contribute to the company's competitive advantage in the pharmaceutical industry.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Micro Labs Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Micro Labs has a strong track record in the pharmaceutical industry, with a diverse product portfolio and a significant presence in both domestic and international markets. The company's export value of $463.6 million USD, with 14,326 shipments across 76 products in 21 therapeutic categories, reflects its extensive reach and reliability as a supplier. The top five products—Amoxicillin, Potassium, Gabapentin, Losartan, and Esomeprazole—account for a substantial portion of the company's export value, indicating a focused and efficient supply chain. Micro Labs' adherence to international quality standards and regulatory compliance further enhances its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure the quality and compliance of Micro Labs' products:

FDA Approval: Confirm that the manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA) and that the products have FDA approvals. This can be verified through the FDA's official website or by contacting the FDA directly.

TransData Nexus Research · FDA, WHO, EMA regulatory databases

Frequently Asked Questions — Micro Labs Limited

How many pharmaceutical products does Micro Labs Limited export from India?

Micro Labs Limited exports 76 pharmaceutical products across 21 therapeutic categories. The top exports are Amoxicillin ($63.3M), Potassium ($25.1M), Gabapentin ($22.7M), Losartan ($20.5M), Esomeprazole ($20.4M). Total export value is $463.6M.

What is Micro Labs Limited's total pharmaceutical export value?

Micro Labs Limited's total pharmaceutical export value is $463.6M, based on 14,326 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Micro Labs Limited the #1 Indian exporter?

Micro Labs Limited is the #1 Indian exporter in 6 products: Amoxicillin (10.4% market share), Cefixime (11.0% market share), Clarithromycin (15.7% market share), Trimethoprim (21.8% market share), Sulfamethoxazole (28.1% market share).

What therapeutic categories does Micro Labs Limited cover?

Micro Labs Limited exports across 21 therapeutic categories. The largest are Antibiotics (21.2%, 6 products), Cardiovascular (17.3%, 14 products), Advanced Antibiotics (12.2%, 14 products).

Get Full Micro Labs Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.

Micro Labs Limited

Micro Labs Limited — Export Portfolio & Destination Treemap

Who is Micro Labs Limited? — Company Overview & Market Position

What Does Micro Labs Limited Export? — Product Portfolio Analysis

Top Products by Export Value

Micro Labs Limited Therapeutic Categories — 21 Specializations